Compare ARK Genomic Revolution ETF (ARKG) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.2. Which is the better fit depends on your goals.
| ARKG | VEA | |
|---|---|---|
Sector | Sector/Thematic | — |
52-Week High | $43.57 | $72.39 |
52-Week Low | $23.09 | $56.02 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
VEA trades at $70.99, up 0.37% on the day, with technical indicators showing a neutral to bearish bias. The ETF provides low-cost exposure to developed international equities, with a 0.03% expense ratio and over $304 billion in assets under management. Recent news highlights its competitive performance against U.S. benchmarks and peer ETFs, with strong returns in developed markets.
Outlook remains positive due to valuation discounts versus U.S. stocks and diversification benefits. Risks include currency fluctuations and geopolitical developments in Europe and Japan. The dividend yield of approximately 3.1% adds income appeal, but investors should monitor central bank policy shifts impacting international equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
